secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001193125-26-140152
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO
-----------------------------------------------------------------------

- Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.
- Mr. Levine to receive $490k salary over 12 months, $61.7k 2025 bonus, and 50% of 2026 target bonus pro-rated.
- Erlander signs consulting agreement; stock options vest through June 2026, then exercisable for 12 months.
- Levine's vested options exercisable for 12 months after separation date.
- Erlander resigns from board of directors effective March 27, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526140152/0001193125-26-140152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526140152/crdf-20260327.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-140152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer